G. R. Galstyan

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.7K citations · Full text

Diabetes Management, Cardiovascular Disease, Diabetes +6

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 586 citations

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin‐treated type 1 and type 2 diabetes: the global <scp>HAT</scp> study

Kamlesh Khunti, Saud Alsifri, Ronnie Aronson et al. · Diabetes Obesity and Metabolism · 2016 · 260 citations · Full text

Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition

Marina V. Shestakova, Olga K. Vikulova, G. R. Galstyan et al. · Diabetes Mellitus · 2019 · 255 citations · Full text

Family Medicine, Russian Federation, Logistic Analysis +19

The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study)

Marina V. Shestakova, G. R. Galstyan · Diabetes Mellitus · 2016 · 251 citations · Full text

Metabolic Syndrome, Nation Study, Diabetes Management +14